Skip to main content

Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer

Buy Article:

$63.00 plus tax (Refund Policy)


Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds' antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.

Keywords: Human γ δ T cells; bisphosphonates; immunotherapy; phosphoantigens; tumors

Document Type: Research Article


Affiliations: Dipartimento di Biopatologia e Metodologie Biomediche, Universita di Palermo, Corso Tukory 211,Palermo 90134 Italy.

Publication date: May 1, 2008

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more
Real Time Web Analytics